Literature DB >> 12610314

Thiopurine therapy: when to start and when to stop.

Dermot P B McGovern1, Simon P L Travis.   

Abstract

The thiopurines azathioprine and 6-mercaptopurine are effective both for active disease and for maintaining remission in both Crohn's disease and ulcerative colitis. This review describes criteria for starting thiopurines (two or more courses of steroids in a calendar year, relapse as prednisolone is reduced below 15 mg/day, within 6 weeks of stopping steroids) and the benefits of continuing treatment for up to 5 years. Challenging issues, such as thiopurine intolerance, relative merits of azathioprine, 6-mercaptopurine, monitoring therapy and thiopurines in pregnancy are addressed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610314     DOI: 10.1097/01.meg.0000049993.68425.13

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

1.  Guidelines for the management of inflammatory bowel disease in adults.

Authors:  M J Carter; A J Lobo; S P L Travis
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  Crohn's disease or abdominal tuberculosis?

Authors: 
Journal:  Gut       Date:  2007-12       Impact factor: 23.059

3.  European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

Authors:  S P L Travis; E F Stange; M Lémann; T Oresland; Y Chowers; A Forbes; G D'Haens; G Kitis; A Cortot; C Prantera; P Marteau; J-F Colombel; P Gionchetti; Y Bouhnik; E Tiret; J Kroesen; M Starlinger; N J Mortensen
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

Review 4.  Relapse rate following azathioprine withdrawal in maintaining remission for Crohn's disease: a meta-analysis.

Authors:  Helen French; A Mark Dalzell; Ramesh Srinivasan; Wael El-Matary
Journal:  Dig Dis Sci       Date:  2011-04-08       Impact factor: 3.199

5.  The haemotoxicity of azathioprine in repeat dose studies in the female CD-1 mouse.

Authors:  Gemma Molyneux; Frances M Gibson; Christabelle M Chen; Harpal K Marway; Sean McKeag; Charles V J Mifsud; Andrew M Pilling; Matthew J Whayman; John A Turton
Journal:  Int J Exp Pathol       Date:  2008-04       Impact factor: 1.925

6.  Infliximab to treat severe ulcerative colitis.

Authors:  Dídia Bisamra Cury; Marcelo de Souza Cury; Geraldo Vinicius Hemerly Elias; Sender Jankiel Mizsputen
Journal:  World J Gastroenterol       Date:  2009-04-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.